Company Announcements

Grant of Options

19 August 2022

LONDON, U.K AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that it has granted options ("Options") over a total of 1,080,000  common stock of US$0.001 ("Common Stock") in the Company ("Shares") to various new employees of the Company in accordance with the Company's 2018 Long Term Incentive Plan. The Options vest over a three-year period from the date of grant, expire after ten years and have an exercise price of 35.5 pence.


For further information, please contact:

Spectral MD Holdings, Ltd.

Wensheng Fan, Chief Executive Officer

Nils Windler, Chief Financial Officer

via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

+44 (0) 20 3470 0470

Stuart Gledhill / Caroline Rowe (Corporate Finance)

Vadim Alexandre / Rob Rees (Sales and Corporate Broking)

Stifel Nicolaus Europe Limited (Joint Broker)

+44 (0) 20 7710 7600

Charles Hoare / Ben Maddison / Will Palmer-Brown

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or [email protected]

Sam Allen / Alice Woodings

+44 (0)75 0255 8258 / +44 (0) 7407 804654


About Spectral MD:  

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.

[email protected]